PERSONALIZED ONCOLOGY SERVICES TEAM

David Sidransky, M.D., Co-Founder and Chairman
Eric K. Rowinsky, M.D., Chief Medical Officer (Consultant)
Manuel Hidalgo, M.D., Ph.D., Chief Scientist
Guy Malchi, M.B.A., General Manager (UK Ltd.)
James Martell, Co-Founder

David Sidransky, M.D., Co-Founder and Chairman*

A world renowned oncologist and research scientist, Dr. Sidransky was named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital.

* The participation of Dr. Sidransky in Champions Biotechnology does not constitute or imply involvement or endorsement by the Johns Hopkins University School of Medicine or the Johns Hopkins Health System.

Eric K. Rowinsky, M.D., Chief Medical Officer (Consultant)

Dr. Rowinsky received his B.A. degree from New York University and his M.D. from the Vanderbilt University School of Medicine. Following his residency in internal medicine at the University of California, he completed fellowship training in medical oncology and clinical pharmacology at the Johns Hopkins University School of Medicine. From 1987 to 1996, Dr. Rowinsky served as an Associate Professor of Oncology at the Johns Hopkins University School of Medicine where he performed seminal clinical development and pharmacologic studies on paclitaxel, docetaxel, irinotecan, topotecan, among other agents. From 1996 to 2004, he served as the Director of Clinical Research and later Director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio where he held the SBC Endowed Chair for Early Drug Development and was a lead investigator on early developmental studies of many classes of targeted therapeutics such as erlotinib, gefitinib, panitumumab, temsirolimus, ridaforolimus, trabectedin, and many other agents. He was also Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio from 1996 to 2006. From 2005 to 2007, Dr. Rowinsky served as the Chief Medical Officer and Senior Vice President at ImClone Systems, responsible for clinical development and regulatory affairs at ImClone Systems. From 2007 to 2009, he was an Executive Vice President of ImClone Systems, which became a wholly-owned subsidiary of Eli Lilly after its acquisition. He is also an Adjuvant Professor of Medicine at New York University School of Medicine and currently serves as a scientific advisor to ImClone Systems and other pharmaceutical and biotechnology companies, with a focus on cancer therapeutic development. Prior to joining ImClone in 2005, Dr. Rowinsky was a longstanding NCI principal investigator on U01 anticancer drug development grants and integrally involved in pivotal clinical and preclinical investigations which lead to the development of both classical chemotherapeutics and targeted therapies including a wide variety of cytotoxic and targeted anticancer therapeutics.

Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs, an Associate Editor and Editorial Board Member of Cancer Research (Associate Editor and Reviews Editor), Clinical Cancer Research, Annals of Oncology, Cancer Biology and Therapy and several other oncology journals and has published approximately 300 manuscripts in both the preclinical and clinical research fields. He has also served on the Board of Directors, Scientific Advisory Board and Project Advisory Boards of a large number of pharmaceutical and biotechnology companies and has advised and/or presented aspects of New Drug Applications to the FDA on several occasions. Dr. Rowinsky’s honors include receipt of the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award for outstanding achievement of a young researcher in clinical cancer therapeutics. He has also served on the Board of Scientific Counselors of the NCI.

Manuel Hidalgo, M.D., Ph.D., Chief Scientist

Manuel Hidalgo, M.D., Ph.D. served as Director and as Scientific Advisor from June, 2007 until March, 2008. Dr. Hidalgo is a Professor of Oncology at the Universidad CEU San Pablo, Director of the Centro Integral Oncologia "Clara Campal" and Director of the Clinical Research Program at CNIO all in Madrid, Spain. Dr. Hidalgo is serving on the Scientific Advisory Boards of private and public companies, including Systems Medicine, Tau Therapeutics, Targeted Molecular Diagnostics and Monogram Biosciences. Dr. Hidalgo is considered a leading researcher in the field of targeted therapies for the treatment of cancer in patients with solid tumors. Dr. Hidalgo has published over 140 papers in prestigious cancer journals as well as numerous chapters in important text books. He has received numerous awards including an AACR Young Investigator Award, an NCI-EORTC fellowship and an ASCO Career Development Award. He has served on the editorial board of the Journal of Clinical Oncology and Clinical Cancer Research and is a Senior Editor for Molecular Cancer Therapeutics. Dr. Hidalgo has chaired the AACR and ASCO Program Committee in developmental therapeutics on numerous occasions and is frequently invited to speak at major national and international meetings. He chairs the Pancreatic Cancer Research Team, a nonprofit organization focused on clinical trials in pancreatic cancer, and is also a member of the NCI Developmental Therapeutics Study. Dr. Hidalgo is one of the inventors of the BPU sulfur analog compounds that the Company acquired in February, 2007.

Guy Malchi, M.B.A., General Manager (UK Ltd.)

Guy Malchi brings more than twelve years of leadership and management experience within the bio-pharma industry. Mr. Malchi’s expertise is in deploying innovative strategies and developing new business relationships. Mr. Malchi previously served as Chief Executive Officer for Optimata Ltd., a development stage biopharmaceutical company focused on developing biosimulation technologies that predict cancer patients’ response to treatment. Prior to that, Mr. Malchi was based in London with Tefen Ltd. (Tel-Aviv stock exchange: TEFN), an international management consulting firm where he served as the founding partner of Tefen’s successful European life science practice. Mr. Malchi received a bachelor’s degree in Industrial Engineering from Tel-Aviv University and an executive master’s degree in Business Administration from London Business School.

James Martell, Co-Founder

Jim Martell is passionate in his pursuit of personalized cancer treatments for patients and their families. His involvement began with the search for a cure for his best friend's rare and very aggressive cancer. This journey gave Jim unique insight into the patient and advocate's point of view. The result was a profound personal transformation that changed him and the direction of his public company and, in 2007, became the genesis of Champions Biotechnology. Prior to his involvement in 1985 with Champions, Jim was a partner in consulting firms specializing in international joint ventures, capital and corporate financing, technology transfer and international business development. Jim received his Bachelor of Science degree in Chemistry and Master of Science degree in Geochemistry from George Washington University.